HyposMatter.com provides users with an overview of hypoglycemia as a barrier to glucose control, the direct economic impact of hypoglycemia, and consequences associated with hypoglycemia
to visit HyposMatter.com and learn more!
to learn more about hypoglycemia and how it impacts glucose control, costs, and consequences
References: 1. American Diabetes Association. Standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(suppl 1):S1-S159. 2. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med. 1991;90(4):450-459. 3. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665-671. 4. Heller SR, Frier BM, Hersløv ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33(4):471-477. 5. Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17(3):176-183. 6. Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis. 2011;11(suppl 1):S10-S12.
To ensure receipt of future emails, please add email@example.com to your address book.
Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.
To unsubscribe from future communications from Novo Nordisk Inc., please click here. Additionally, you can unsubscribe from future Novo Nordisk communications by calling 1-877-744-2579 or sending a brief note with your name and address to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2018 Novo Nordisk All rights reserved. US18DI00011 May 2018